Arribas, A. J., Napoli, S., Gaudio, E., Herbaux, C., Cannas, E., Tarantelli, C., . . . Bertoni, F. PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas. Elsevier.
Chicago Style (17th ed.) CitationArribas, Alberto J., et al. PI3Kδ Activation, IL-6 Overexpression, and CD37 Loss Cause Resistance to Naratuximab Emtansine in Lymphomas. Elsevier.
MLA (9th ed.) CitationArribas, Alberto J., et al. PI3Kδ Activation, IL-6 Overexpression, and CD37 Loss Cause Resistance to Naratuximab Emtansine in Lymphomas. Elsevier.
Warning: These citations may not always be 100% accurate.